Arcus Biosciences Inc. (RCUS)
NYSE NYSE Primary 
Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)
Domvanalimab shows promising results in gastric cancer, with a 56% response rate and median progression-free survival of 12.9 months. Quemlicustat sees progress with Taiho exercising rights in Asia, while etrumadenant shows positive results in colorectal cancer trials. Arcus Biosciences pipeline continues to show potential, but TIGIT failures in the industry pose a significant risk to the company's outlook.
Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript
Arcus Biosciences, Inc. (NYSE:RCUS ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Pia Eaves – Vice President-Investor Relations and Strategy Terry Rosen – Chief Executive Officer Jennifer Jarrett – Chief Operating Officer Bob Goeltz – Chief Financial Officer Dimitry Nuyten – Chief Medical Officer Conference Call Participants Yigal Nochomovitz – Citi Jonathan Miller – Evercore Daina Graybosch – Leerink Partners Asthika Goonewardene – Truist Securities Operator Good afternoon, thank you for attending today's Arcus Biosciences Second Quarter 2024 Earnings Call. My name is Tamiya and I will be your moderator for today's call.
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.04 per share a year ago.
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Arcus Biosciences (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is The Options Market Predicting a Spike In Arcus Biosciences (RCUS) Stock?
Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.
